natgillin/translations-raw huggingface dataset:
After preparation, the solution to inject is clear to slightly opalescent and colourless. 
Po pripravi je raztopina, ki se injicira, bistra do blago opalescentna in brezbarvna.
Connect the solvent syringe to the vial adapter by inserting the tip of the syringe into the adapter opening. 
Injekcijsko brizgo z vehiklom povežite z nastavkom na viali tako, da konico injekcijske brizge vtaknete v odprtino nastavka.
Do not use if the product has expired. 
Zdravila, ki mu je potekel rok uporabnosti, ne uporabite.
Protect the solution from direct sunlight. 
Raztopino zaščitite pred neposredno sončno svetlobo.
Decreased appetite 
Presnovne in prehranske motnje zmanjšan apetit občasni
ALPROLIX 250 IU powder for injection ALPROLIX 500 IU powder for injection ALPROLIX 1000 IU powder for injection ALPROLIX 2000 IU powder for injection ALPROLIX 3000 IU powder for injection eftrenonacog alfa recombinant coagulation factor IX IV 
ALPROLIX 250 i.e. prašek za injekcijo ALPROLIX 500 i.e. prašek za injekcijo ALPROLIX 1000 i.e. prašek za injekcijo ALPROLIX 2000 i.e. prašek za injekcijo ALPROLIX 3000 i.e. prašek za injekcijo eftrenonacogum alfa rekombinantni koagulacijski faktor IX i.v.
ALPROLIX contains the active substance eftrenonacog alfa, recombinant coagulation factor IX, Fc fusion protein. 
Zdravilo ALPROLIX vsebuje učinkovino eftrenonakog alfa, rekombinantni koagulacijski faktor IX,
ALPROLIX 500 IU powder and solvent for solution for injection ALPROLIX 1000 IU powder and solvent for solution for injection ALPROLIX 2000 IU powder and solvent for solution for injection ALPROLIX 3000 IU powder and solvent for solution for injection eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein This medicine is subject to additional monitoring. 
ALPROLIX 500 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 1000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 2000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 3000 i.e. prašek in vehikel za raztopino za injiciranje eftrenonakog alfa (eftrenonacogum alfa), rekombinantni koagulacijski faktor XI, fuzijska beljakovina Fc Za to zdravilo se izvaja dodatno spremljanje varnosti.
Once you have prepared ALPROLIX it should be used right away. 
Pripravljeno zdravilo ALPROLIX takoj uporabite.
Animal reproduction studies have not been conducted with ALPROLIX. 
Študij o vplivu zdravila ALPROLIX na sposobnost razmnoževanja pri živalih niso izvedli.
Alternatively, ALPROLIX may be stored at room temperature (up to 30°C) for a single period not exceeding 6 months. 
Zdravilo ALPROLIX lahko shranite tudi pri sobni temperaturi (do 30 °C), in sicer za enkratno obdobje največ 6 mesecev.
ALPROLIX 250 IU powder and solvent for solution for injection Each vial contains nominally 250 IU eftrenonacog alfa. 
ALPROLIX 250 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 250 i.e. eftrenonakoga alfa (eftrenonacogum alfa).
The median overall dose to treat a bleeding episode was 51.47 IU/kg (IQR: 35.21-61.73) in the weekly prophylaxis arm, 49.62 IU/kg (IQR: 35.71-94.82) in the individualised interval prophylaxis arm and 46.58 IU/kg (IQR: 33. 
49,62 i.e./kg (IQR: 35,71-94,82) pri profilaktičnem individualiziranem intervalu in 46,58 i.e./kg (IQR:
In a placental transfer study, ALPROLIX has been shown to cross the placenta in small amounts in mice. 
ALPROLIX v majhnih količinah prehaja skozi posteljico.
powder and solvent for solution for injection 
prašek in vehikel za raztopino za injiciranje
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock). 
pekoč občutek in zbadanje na mestu infundiranja, mrzlico, zardevanje, generalizirano urtikarijo, glavobol, koprivnico, hipotenzijo, letargijo, navzeo, nemirnost, tahikardijo, stiskanje v prsnem košu, mravljinčenje,
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE IN IZDELOVALEC
Talk to your doctor, pharmacist or nurse before using ALPROLIX. 
Pred začetkom uporabe zdravila ALPROLIX se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
ALPROLIX 2000 IU powder and solvent for solution for injection Each vial contains nominally 2000 IU eftrenonacog alfa. 
ALPROLIX 2000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 2000 i.e. eftrenonakoga alfa (eftrenonacogum alfa).
How ALPROLIX works 
Delovanje zdravila ALPROLIX
In children below the age of 12 years, higher doses or more frequent injections may be needed and the usual dose is 50 to 60 IU per kg of body weight, given once every 7 days. 
12 let, bodo morda potrebni večji odmerki ali pogostejše injiciranje, običajni odmerek pa je od 50 do
Intravenous use, after reconstitution. 
intravenska uporaba po rekonstituciji Pred uporabo preberite priloženo navodilo!
Remove the plastic flip-top cap from the ALPROLIX vial 
Z viale z zdravilom ALPROLIX snemite plastično zaporko.
ALPROLIX 500 IU powder and solvent for solution for injection Each vial contains nominally 500 IU eftrenonacog alfa. 
ALPROLIX 500 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 500 i.e. eftrenonakoga alfa (eftrenonacogum alfa).
ALPROLIX 3000 IU powder and solvent for solution for injection Each vial contains nominally 3000 IU eftrenonacog alfa. 
ALPROLIX 3000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 3000 i.e. eftrenonakoga alfa (eftrenonacogum alfa).
Slowly depress the plunger rod to inject all the solvent into the ALPROLIX vial. 
Nosilec za bat brizge počasi potiskajte, da injicirate celotno količino vehikla v vialo z zdravilom
How to store ALPROLIX 
Shranjevanje zdravila ALPROLIX
ALPROLIX is administered by intravenous (IV) injection after dissolving the powder for injection with the solvent supplied in the pre-filled syringe. 
injekcije potem, ko se prašek za injiciranje raztopi z vehiklom v napolnjeni injekcijski brizgi.
ALPROLIX 250 IU powder and solvent for solution for injection ALPROLIX 500 IU powder and solvent for solution for injection ALPROLIX 1000 IU powder and solvent for solution for injection ALPROLIX 2000 IU powder and solvent for solution for injection ALPROLIX 3000 IU powder and solvent for solution for injection eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein 
ALPROLIX 250 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 500 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 1000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 2000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 3000 i.e. prašek in vehikel za raztopino za injiciranje eftrenonacogum alfa rekombinantni koagulacijski faktor IX, fuzijska beljakovina Fc
The solution should appear clear to slightly opalescent and colourless. 
Videz raztopine mora biti bister do rahlo opalescenten in brezbarven.
ALPROLIX 1000 IU powder and solvent for solution for injection Each vial contains nominally 1000 IU eftrenonacog alfa. 
ALPROLIX 1000 i.e. prašek in vehikel za raztopino za injiciranje Ena viala vsebuje nominalno 1000 i.e. eftrenonakoga alfa (eftrenonacogum alfa).
During the shelf-life, the product may be stored at room temperature (up to 30°C) for a single period not exceeding 6 months. 
Zdravilo lahko v roku uporabnosti za eno samo obdobje, ki ne sme biti daljše od 6 mesecev, shranjujete pri sobni temperaturi (do 30 °C).
Slowly pull on the plunger rod to draw back all the solution through the vial adapter into the syringe. 
Počasi vlecite za nosilec za bat brizge, da izvlečete vso raztopino skozi nastavek na viali v injekcijsko brizgo.
ALPROLIX 250 IU powder and solvent for solution for injection ALPROLIX 500 IU powder and solvent for solution for injection ALPROLIX 1000 IU powder and solvent for solution for injection ALPROLIX 2000 IU powder and solvent for solution for injection ALPROLIX 3000 IU powder and solvent for solution for injection 
ALPROLIX 250 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 500 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 1000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 2000 i.e. prašek in vehikel za raztopino za injiciranje ALPROLIX 3000 i.e. prašek in vehikel za raztopino za injiciranje
Dose and duration of the substitution therapy depend on the severity of the factor IX deficiency, on the location and extent of the bleeding and on the patient's clinical condition. 
Odmerjanje Odmerek zdravila in trajanje nadomestnega zdravljenja sta odvisna od stopnje pomanjkanja faktorja IX,
Repeat injection every 24 to 48 hours until pain and acute disability are resolved. 
Injiciranje ponavljajte vsakih 24 do 48 ur ali več,
Haemorrhage Early haemarthrosis, muscle bleeding or oral bleeding 
krvavitev v mišico ali krvavitev v ustni votlini
Uncommon side effects (may affect up to 1 in 100 people): dizziness, taste alteration, bad breath, feeling tired, pain at the injection site, rapid heartbeat, blood in the urine (haematuria), pain in your side (renal colic), low blood pressure, and decreased appetite. 
slab zadah, občutek utrujenosti, bolečina na mestu injiciranja, hitro utripanje srca, kri v urinu (hematurija),
Turn the plunger rod firmly clockwise until it is securely seated in the syringe plunger. 
Nosilec čvrsto obračajte v smeri urnega kazalca, da se varno usede v bat injekcijske brizge.
After reconstitution, each mL of solution for injection contains approximately 50 IU eftrenonacog alfa. 
Po rekonstituciji vsebuje en mililiter raztopine za injiciranje približno 50 i.e. eftrenonakoga alfa.
The median overall dose to treat a bleeding episode was 68.22 IU/kg (interquartile range, 
Mediana celokupnega odmerka za zdravljenje epizode krvavitve je bila 68,22 i.e./kg (interkvartilni razpon 50,89-126,19).
After reconstitution, each mL of solution for injection contains approximately 400 IU eftrenonacog alfa. 
Po rekonstituciji vsebuje en mililiter raztopine za injiciranje približno 400 i.e. eftrenonakoga alfa.
Detach the syringe from the vial adapter by gently pulling and turning the vial counterclockwise. 
Injekcijsko brizgo z nežnim vlečenjem in obračanjem viale v nasprotno smer urnega kazalca ločite od nastavka na viali.
B) 5 mL Solvent in pre-filled syringe C) 1 Plunger rod 
A) 1 vialo s praškom B) 5 ml vehikla v napolnjeni injekcijski brizgi C) 1 nosilec za bat brizge D) 1 nastavek za vialo E) 1 infuzijski komplet F) 2 alkoholna zloženca G) 2 obliža
The calculation of the required dose of recombinant factor IX Fc is based on the empirical finding that 1 International Unit (IU) factor IX per kg body weight raises the plasma factor IX activity by 1% of normal activity (IU/dL). 
Izračun potrebnega odmerka rekombinantnega faktorja IX Fc temelji na empirični ugotovitvi, da
After reconstitution, each mL of solution for injection contains approximately 600 IU eftrenonacog alfa. 
Po rekonstituciji vsebuje en mililiter raztopine za injiciranje približno 600 i.e. eftrenonakoga alfa.
After reconstitution, each mL of solution for injection contains approximately 200 IU eftrenonacog alfa. 
Po rekonstituciji vsebuje en mililiter raztopine za injiciranje približno 200 i.e. eftrenonakoga alfa.
Hypotension 
Krvavitev
After reconstitution, each mL of solution for injection contains approximately 100 IU eftrenonacog alfa. 
Po rekonstituciji vsebuje en mililiter raztopine za injiciranje približno 100 i.e. eftrenonakoga alfa.
Nervous system disorders 
Žilne bolezni hipotenzija občasni
The prepared solution will be clear to slightly opalescent and colourless. 
Pripravljena raztopina mora biti bistra do rahlo opalescentna (bisernata) in brezbarvna.
Intravenous use. 
Navodilo za uporabo
L-histidine 
(rFIXFc).
Powder: 250 IU eftrenonacog alfa (approx. 50 IU/mL after reconstitution), Powder: 500 IU eftrenonacog alfa (approx. 100 IU/mL after reconstitution) Powder: 1000 IU eftrenonacog alfa (approx. 200 IU/mL after reconstitution) Powder: 2000 IU eftrenonacog alfa (approx. 400 IU/mL after reconstitution) Powder: 3000 IU eftrenonacog alfa (approx. 600 IU/mL after reconstitution) 
200 i.e./ml po rekonstituciji) Prašek: 2000 i.e. eftrenonakoga alfa (pribl.
… or onto a small amount of food. 
… ali na majhno količino hrane.
Avoid eye contact. 
Preprečite stik z očmi.
No significant gender effect was seen. 
Značilnih učinkov spola niso opazili.
The terminal elimination half-life (t1/2) ranged from 7.3 hours to 8.6 hours, with mean value 7.7 hours. 
Končni eliminacijski razpolovni čas (t1/2) je bil v razponu od 7,3 ure do 8,6 ur, s povprečno vrednostjo 7,7 ur.
The CVMP agreed that the periodic safety update report (PSUR) cycle would be re-started at 6 months, 12 months and 24 months following authorisation of the extension, as detailed in the CVMP assessment report. 
CVMP se je strinjal, da se cikel rednih posodobljenih poročil o varnosti zdravila (PSUR) ponovno začne izvajati 6 mesecev, 12 mesecev in 24 mesecev po odobritvi razširitve, kot je podrobno navedeno v poročilu o oceni CVMP.
The target SBP range is between 120 and 140 mmHg. 
Ciljni razpon SBP je med 120 in 140 mm Hg.
See section “Contraindications”. 
Glejte poglavje "Kontraindikacije".
The product is to be administered once daily directly into the mouth or with a small amount of food. 
Zdravilo se daje neposredno v usta ali z majhno količino hrane enkrat na dan.
If the SBP increases over the course of the disease the daily dose may be increased again up to 2 mg/kg. 
Če se SBP med potekom bolezni poveča, se lahko dnevni odmerek ponovno poveča do 2 mg/kg.
ATCvet code: QC09CA07 
Oznaka ATC vet: QC09CA07.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: - zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) - pogosti (pri več kot 1, toda manj kot 10 od 100 zdravljenih živali) - občasni (pri več kot 1, toda manj kot 10 od 1.000 zdravljenih živali) - redki (pri več kot 1, toda manj kot 10 od 10.000 zdravljenih živali) - zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri)
Date of first authorisation: Date of last renewal: 
Datum pridobitve dovoljenja: Datum zadnjega podaljšanja dovoljenja:
PSURs: 
PSUR:
Treatment of systemic hypertension in cats. 
Zdravljenje sistemske hipertenzije pri mačkah.
Elevated liver enzymes have been very rarely observed and values normalised within a few days following cessation of therapy. 
Redko so opazili zvišanje jetrnih encimov, vrednosti pa so se v nekaj dneh po prekinitvi zdravljenja normalizirale.
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary products. 
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili za uporabo v veterinarski medicini.
To avoid contamination, use the provided syringe only to administer Semintra. 
Da preprečite onesnaženje, uporabljajte priloženo brizgo samo za dajanje zdravila Semintra.
Substances acting on the RAAS may lead to a reduction in glomerular filtration rate and worsening renal function in cats with severe kidney disease. 
Snovi, ki delujejo na RAAS, lahko privedejo do zmanjšanja hitrosti glomerularne filtracije in poslabšanja ledvične funkcije pri mačkah s hudo ledvično boleznijo.
The safety and efficacy of telmisartan for the management of systemic hypertension above 200 mmHg has not been investigated. 
Varnost in učinkovitost telmisartana za zdravljenje sistemske hipertenzije nad 200 mmHg ni bila raziskana.
Turn the bottle/syringe upside down. 
Plastenko/brizgo obrnite navzdol.
In case of accidental eye contact, rinse eyes with water. 
V primeru nenamernega stika z očmi jih izperite z vodo.
In vitro studies in human, dog, mouse and rat plasma showed a high plasma protein binding (>99.5%), mainly to albumin and α-1-acid glycoprotein. 
Študije in vitro v plazmi ljudi, psov, miši in podgan kažejo na visoko vezavo na beljakovine v plazmi (> 99,5 %), pretežno na albumin in α-1 kisli glikoprotein.
Active substance: Telmisartan 
Učinkovina: telmisartan
After oral administration, telmisartan is almost exclusively excreted in the faeces mainly as the unchanged active substance. 
Po peroralni uporabi se telmisartan izloči skoraj izključno v blatu, pretežno kot nespremenjena učinkovina.
As determined by AUC, food consumption does not affect the overall extent of absorption of telmisartan. 
Kot je bilo ugotovljeno z AUC, uživanje hrane ne vpliva na splošni obseg absorpcije telmisartana.
Due to the combination of these pharmacodynamic properties, telmisartan is an appropriate treatment for cats with concomitant hypertension and CKD. 
Zaradi kombinacije teh farmakodinamičnih lastnosti je telmisartan primeren za zdravljenje mačk s sočasno hipertenzijo in KBL.
If SBP is below the target or if there are concurrent signs of hypotension, please refer to section 4.5. 
Če je SBP pod ciljno vrednostjo, ali če sočasno obstajajo znaki hipotenzije, glejte poglavje 4.5.
Do not use during pregnancy or lactation (see also section 4.7). 
Ne uporabite v obdobju brejosti ali laktacije (glejte tudi poglavje 4.7).
EXP {month/year} Once opened use by .... 
EXP {mesec/leto} Odprto zdravilo uporabite do....
The absolute bioavailability after oral administration was found to be 33%. 
Ugotovili so, da je absolutna biološka razpoložljivost po peroralnem dajanju 33 %.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the bottle after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na škatli in steklenici po EXP.
Semintra is an oral solution and is well accepted by most cats. 
Zdravilo Semintra je peroralna raztopina, ki jo večina mačk dobro sprejme.
Pull the plunger out until the end of the plunger corresponds to the amount needed in ml. 
Bat vlecite, dokler konec bata ne ustreza potrebni količini v ml.
Do not use during pregnancy and lactation (see section 4.3). 
Ne uporabljajte med brejostjo in laktacijo (glejte poglavje 4.3).
Push down and turn cap to open the bottle. 
Zaporko potisnite navzdol in jo obrnite, da plastenko odprete.
Shelf life of the veterinary medicinal product as packaged for sale (30 ml or 100 ml): 3 years. 
Rok uporabnosti zdravila v pakiranju za prodajo (30 ml ali 100 ml): 3 leta.
If SBP is below the target or if there are concurrent signs of hypotension, please refer to the “Special warnings” section. 
Če je SBP pod ciljno vrednostjo, ali če sočasno obstajajo znaki hipotenzije, glejte poglavje 'Posebna opozorila'.
EXP {month/year} Once opened use within 6 months. 
EXP {mesec/leto} Odprto zdravilo uporabite v roku 6 mesecev.
The glucuronidation resulted in the formation of the 1-O-acylglucuronide metabolite of telmisartan. 
Glukuronizacija povzroči nastajanje 1-O-acilglukuronidnega presnovka telmisartana.
See section “Pregnancy and lactation”. 
Glejte poglavje "Brejost in laktacija".
The safety and efficacy of telmisartan has not been tested in cats under the age of 6 months. 
Varnosti in učinkovitosti telmisartana niso preskusili pri mačkah, starih manj kot 6 mesecev.
The combination of telmisartan with such agents may lead to additive hypotensive effects or may alter renal function. 
Kombinacija telmisartana s takimi zdravili lahko privede do aditivnih hipotenzivnih učinkov ali lahko spremeni delovanje ledvic.
Clear, colourless to yellowish viscous solution. 
Bistra, brezbarvna do rumenkasta viskozna raztopina.
After 4 weeks, the dosage of telmisartan may be reduced in cats with systolic blood pressure (SBP) of less than 140 mmHg (in 0.5 mg/kg increments) at the discretion of the veterinarian. 
Po 4 tednih se lahko odmerek telmisartana pri mačkah s sistoličnim krvnim tlakom (SBP) manj kot 140 mm Hg (pri povečanjih za 0,5 mg/kg) zmanjša po presoji veterinarja.
From in vitro and ex vivo studies with feline liver microsomes it can be concluded that telmisartan is effectively glucuronidated in the cat. 
Iz študij in vitro in ex vivo na mikrosomih mačjih jeter je mogoče sklepati, da se telmisartan pri mačkah učinkovito glukuronizira.
The dosing regimen for hypertensive cats with concomitant chronic kidney disease is as described above except that for these cats the recommended minimum effective dose is 1 mg/kg. 
Režim odmerjanja za hipertenzivne mačke s sočasno kronično boleznijo ledvic je opisan zgoraj, razlika je le v tem, da je za te mačke priporočeni efektivni najmanjši odmerek 1 mg/kg.
Due to the mode of action of the veterinary medicinal product, transient hypotension may occur. 
Zaradi načina delovanja zdravila za uporabo v veterinarski medicini se lahko pojavi prehodna hipotenzija.
The dosage of telmisartan should be reduced if systolic blood pressure (SBP) is consistently lower than 120 mmHg or if there are concurrent signs of hypotension. 
Odmerek telmisartana je treba zmanjšati, če je sistolični krvni tlak (SBP) dosledno nižji od 120 mm Hg, ali če obstajajo sočasni znaki hipotenzije.
Due to the mode of action of the veterinary medicinal product, transient hypotension (low blood pressure) may occur. 
Zaradi načina delovanja zdravila za uporabo v veterinarski medicini se lahko pojavi prehodna hipotenzija (nizek krvni tlak).
Telmisartan selectively binds to the AT1 receptor and does not show affinity for other receptors, including AT2 or other less characterised AT receptors. 
Telmisartan se selektivno veže na receptorje AT1 in ne kaže afinitete za druge receptorje, vključno z receptorji AT2 in drugimi, manj opredeljenimi receptorji AT.
No clinically relevant accumulation was observed following multiple dose administration once daily for 21 days. 
Po večkratnem odmerjanju enkrat na dan 21 dni niso opazili klinično pomembnega kopičenja.
Pull the plunger out until the end of the plunger corresponds to your cat´s body weight in kilograms. 
Bat vlecite, dokler konec bata ne ustreza telesni masi vaše mačke v kilogramih.
Red blood cell count should be monitored during therapy. 
Med zdravljenjem je treba spremljati število rdečih krvnih celic.
In cats with hypertension it is good clinical practice to regularly monitor blood pressure. 
Pri mačkah s hipertenzijo je redno spremljanje krvnega tlaka dobra klinična praksa.
Push the plunger to empty the contents of the syringe directly into the mouth of the cat 
Potisnite bat, da izpraznite vsebino brizge neposredno v usta mačke…
The receptor binding is long lasting due to the slow dissociation of telmisartan from the AT1 receptor binding site. 
Vezava receptorjev je dolgotrajna zaradi počasne disociacije telmisartana z mesta vezave receptorja AT1.
The safety and efficacy of telmisartan in such patients has not been investigated. 
Varnost in učinkovitost telmisartana pri teh bolnikih ni bila raziskana.
Hypokalaemia is associated with CKD, however telmisartan does not affect potassium excretion, as shown in the clinical field trial in cats. 
S KBL je pogosto povezana hipokaliemija, vendar telmisartan ne vpliva na izločanje kalija, kot so pokazali terenski klinični preskusi pri mačkah.
When using this product in cats with severe kidney disease, it is advisable to monitor renal function (plasma creatinine concentration). 
Pri uporabi tega zdravila pri mačkah s hudo ledvično boleznijo je priporočljivo spremljati delovanje ledvic (koncentracijo kreatinina v plazmi).
The syringe fits onto the bottle and has a ml scale. 
Brizga se prilega na stekleničko in ima merilno lestvico po ml.
The safety of Semintra has not been established in breeding, pregnant or lactating cats. 
Varnost zdravila Semintra v obdobju parjenja, brejosti ali laktacije mačk ni bila ugotovljena.